FCM
KYNB

Frontier Capital Management’s Kyntra Bio KYNB Stock Holding History

Frontier Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,985
Closed -$11.3M – 285
2021
Q2 		$11.3M Buy
+16,985
New +$9.79M 0.08% 225

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frontier Capital Management's KYNB Position: Q3 2021 in Review

Frontier Capital Management sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 16,985 shares — an estimated $11.3M sold.

Frontier Capital Management first reported a position in KYNB in Q2 2021 and held it in 1 quarter. The position peaked at $11.3M in Q2 2021. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • Frontier Capital Management reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • Frontier Capital Management sold 16,985 Kyntra Bio shares in Q3 2021, an estimated $11.3M.
  • Frontier Capital Management first reported a position in Kyntra Bio in Q2 2021 and held it in 1 quarter.
  • Frontier Capital Management's Kyntra Bio position peaked at $11.3M in Q2 2021.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Frontier Capital Management's 13F filing for Q3 2021, filed 19 Oct 2021.